Displaying drugs 401 - 425 of 8500 in total
Selenious acid
Selenious acid is the acid form of sodium selenite, a form of selenium .
Selenium is an essential trace element and antioxidant. It is a cofactor metabolic enzyme regulation. It also plays an important role in maintaining the general health of tissue and muscle and has antioxidant properties. Selenium is...
Approved
Investigational
Matched Mixtures name: … Multitrace-5 ... Multitrace-5 ... Multitrace-5 …
Carmustine
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985)....
Approved
Investigational
Methyltestosterone
A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.
Approved
Matched Synonyms: … 17-beta-Hydroxy-17-methylandrost-4-en-3-one ... 17alpha-Methyl-3-oxo-4-androsten-17beta-ol ... 17beta-Hydroxy-17-methylandrost-4-en-3-one …
Matched Categories: … 3-Oxoandrosten (4) Derivatives …
Matched Categories: … 3-Oxoandrosten (4) Derivatives …
Carya illinoinensis pollen
Carya illinoinensis pollen allergenic extract is used in allergenic testing.
Approved
Matched Mixtures name: … Central Eastern 4 Tree Pollen Mix ... Central Eastern 4 Tree Pollen Mix ... Central Eastern 4 Tree Pollen Mix …
Simethicone
Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … HIDROXDO DE ALUMINIO 4% + HIDROXDO DE MAGNESIO 4% + SIMETICONA 0.4% SUSPENSION ... HIDROXIDO DE ALUMINIO 4% + HIDROXIDO DE MAGNESIO 4% + SIMETICONA 0.4% SUSPENSION …
Matched Products: … METSİL SÜSPANSİYON 40 MG/5 ML, 50 ML ... METSIL 40 MG/5 ML SÜSPANSIYON, 150 ML …
Matched Products: … METSİL SÜSPANSİYON 40 MG/5 ML, 50 ML ... METSIL 40 MG/5 ML SÜSPANSIYON, 150 ML …
Bictegravir
Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Approved
Investigational
Matched Iupac: … (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0 …
Masoprocol
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Approved
Investigational
Matched Synonyms: … meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol …
Matched Iupac: … 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol …
Matched Iupac: … 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol …
Tick-borne encephalitis vaccine (whole virus, inactivated)
Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus Ixodes. The disease course is variable. Some patients will be asymptomatic or experience a mild febrile illness, while others will experience the full course including neurological symptoms. TBE often manifests in a...
Approved
Eflornithine
Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical …
Aclidinium
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Approved
Ledipasvir
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Iupac: … methyl N-[(2S)-1-[(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl ... ]-2-azabicyclo[2.2.1]heptan-3-yl]-1H-1,3-benzodiazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro ... [2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate …
Matched Description: … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, ... 5, and 6 [L852]. ... first line therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, …
Matched Description: … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, ... 5, and 6 [L852]. ... first line therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, …
Padeliporfin
Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin...
Approved
Experimental
Matched Iupac: … palladium(2+) (4S,5S,14R,15R)-10-acetyl-4-(2-carboxyethyl)-15-ethyl-2-(2-methoxy-2-oxoethyl)-5,9,14,19 …
Matched Salts cas: … 698393-30-5 …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings …
Matched Salts cas: … 698393-30-5 …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Iupac: … 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Iupac: … 4-[(1E)-2-{5,5,8,8-tetramethyl-3-[(1H-pyrazol-1-yl)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl] …
Polatuzumab vedotin
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Betahistine
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408]
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to...
Approved
Investigational
Matched Description: … A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 …
Matched Salts cas: … 54856-23-4 ... 133206-34-5 …
Matched Salts cas: … 54856-23-4 ... 133206-34-5 …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Iupac: … N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide …
Articaine
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Approved
Matched Iupac: … methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate …
Matched Mixtures name: … Orabloc 40 mg/ml + 5 Mikrogramm/ml Injektionslösung ... Ubistesin 40 mg/ml + 5 Mikrogramm/ml - Injektionslösung ... Sopira Citocartin 40 mg/ml + 5 Mikrogramm/ml Injektionslösung …
Matched Mixtures name: … Orabloc 40 mg/ml + 5 Mikrogramm/ml Injektionslösung ... Ubistesin 40 mg/ml + 5 Mikrogramm/ml - Injektionslösung ... Sopira Citocartin 40 mg/ml + 5 Mikrogramm/ml Injektionslösung …
N-acetyltyrosine
N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine . It is typically administered as a...
Approved
Matched Synonyms: … (2s)-2-acetylamino-3-(4-hydroxyphenyl)propanoic acid ... (+)-(2s)-2-(acetylamino)-3-(4-hydroxyphenyl)propanoic acid …
Matched Iupac: … (2S)-2-acetamido-3-(4-hydroxyphenyl)propanoic acid …
Matched Mixtures name: … Aminosyn II 5% Inj ... AMINOPLASMAL-5% E INFUSION …
Matched Iupac: … (2S)-2-acetamido-3-(4-hydroxyphenyl)propanoic acid …
Matched Mixtures name: … Aminosyn II 5% Inj ... AMINOPLASMAL-5% E INFUSION …
Benzyl alcohol
Approved
Matched Mixtures name: … ZOLBENE CREMA TOPICA (CALAMINA 5% + OXIDO DE ZINC 5% + ALCOHOL BENCILICO 1%) …
Miltefosine
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Avelumab
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Displaying drugs 401 - 425 of 8500 in total